Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Serina Therapeutics Inc SER

Healthcare Biotechnology
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson’s disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER... see more

Recent & Breaking News (NYSEAM:SER)

Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

GlobeNewswire November 13, 2025

Serina Therapeutics Provides Regulatory Update on SER-252 Program

GlobeNewswire November 3, 2025

Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors

GlobeNewswire October 8, 2025

Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease

GlobeNewswire October 6, 2025

Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease

GlobeNewswire September 9, 2025

Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire September 8, 2025

Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway

GlobeNewswire August 25, 2025

Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

GlobeNewswire August 11, 2025

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

GlobeNewswire July 29, 2025

Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference

GlobeNewswire July 28, 2025

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

GlobeNewswire July 10, 2025

Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

GlobeNewswire July 1, 2025

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

GlobeNewswire June 23, 2025

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

GlobeNewswire June 17, 2025

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

GlobeNewswire June 17, 2025

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"

GlobeNewswire June 9, 2025

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

GlobeNewswire May 22, 2025

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

GlobeNewswire May 14, 2025

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

GlobeNewswire May 8, 2025

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

GlobeNewswire April 29, 2025